A Single Dose Metabolism and Mass Balance Study of 14C-ABR-215050 in Healthy Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-01-31

Study Completion Date

2009-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a single site, open label, single dose, non-randomized study in healthy male and female subjects. The subjects will be evaluated for plasma, urine and feces levels of 14C-ABR-215050 during 21 days.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Mass Balance Recovery, Metabolite Profile and Metabolite Identification of 14C-AB1010 in Healthy Male Subjects

NCT05200169

Healthy Volunteers

COMPLETED EARLY_PHASE1

Mass Balance, Pharmacokinetics, and Metabolism of 14C-labeled ACT-128800 Administered to Healthy Male Subjects

NCT02126956

Pharmacokinetics

COMPLETED PHASE1

A Study in Healthy Men to Find Out How BI 1015550 is Taken up and Handled by the Body

NCT04771286

Healthy

COMPLETED PHASE1

A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]INCB099280 in Healthy Male Participants

NCT06309394

Healthy Participants

COMPLETED PHASE1

A Study to Assess Mass Balance Recovery, Metabolite Profile and Identification of IV and Oral 14C-BC-3781

NCT03131141

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

As a part of the pharmacokinetic documentation, the metabolism and mass balance of 14C-ABR-215050 will be studied in healthy subjects. Female healthy subjects are included in the study in case of expanding the indication to female forms of cancer. In this study a single dose of 1.0 mg of the study drug will be administered orally as a solution under fasted conditions. The absorption and safety profiles for the oral water solution will also be documented.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ABR-215050

Group Type EXPERIMENTAL

ABR-215050

Intervention Type DRUG

1 mg ABR-215050

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ABR-215050

1 mg ABR-215050

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

tasquinimod

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. 40-65 year old male and female subjects.
2. Healthy according to medical history, physical examination and clinical chemistry, urine and hematological laboratory tests.
3. Body Mass Index (BMI) of 18-30.
4. Negative screen for Hepatitis B / C and HIV-infection.
5. Be willing and able to comply with the protocol for the duration of the study.
6. Women of childbearing potential must be neither pregnant nor breast-feeding. Confirmation that the subject is not pregnant must be established by a pregnancy test before the single dose and at study end. Fertile women must be willing to practice reliable methods of contraception. Medically accepted safe methods of contraception for the purpose of this study will include surgical sterilisation, intra-uterine device, diaphragm with spermicide, or condom with spermicide. As interaction studies between ABR-215050 and hormonal (oral or depot) contraceptives have not yet been performed, women using such devices must also use a complementary contraceptive device.
7. Have given written signed informed consent, prior to start of any study-related activities.

Exclusion Criteria

1. Gastrointestinal disorders that may affect drug absorption.
2. Any vaccination within 30 days before start of this study and throughout the study.
3. Blood donation within 90 days before start of this study and for 90 days after the study.
4. Participation in other clinical studies or who have received other investigational drugs within 90 days prior to enrolment. Additionally, subjects previously included into this study and then are withdrawn from the study is not to be re-entered into the study.
5. Perform any planned surgery
6. Any use of nicotine within three (3) months before start of this study and throughout the study.
7. Known or suspected history of alcoholism or drug abuse.
8. Intake of alcoholic beverages for 24 hours prior to the administration of investigational product and for 24 hours after the dose.
9. Intake of caffeine containing beverages 10 hours prior to the administration of investigational product and for 6 hours after the dose.
10. Medication including herbal remedies (vitamins and paracetamol excluded) within 14 days before and throughout the study.

Minimum Eligible Age

40 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes